echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The Food and Drug Administration approved the new coronary plasma therapy, saying its benefits outweigh the risks

    The Food and Drug Administration approved the new coronary plasma therapy, saying its benefits outweigh the risks

    • Last Update: 2020-12-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    BEIJING, Aug. 24 (Xinhua Chinese) -- U.S. President Donald Trump announced at a White House press conference Wednesday evening that the U.S. Food and Drug Administration (FDA) has approved the use of plasma therapy in the treatment of new crown patients.
    , Trump reportedly said at a news conference the same day, "This (plasma therapy) is a powerful treatment, from the blood of recovering patients to convert very strong antibodies, to help infected people with the (new coronavirus)
    ." The
    said in a statement that "the known and potential benefits of the therapy outweigh the known and potential risks," according to the report. The FDA also said the plasma was made from the blood of patients recovering from the new crown, and that more than 70,000 patients have been treated with plasma.
    addition, in response to the U.S. government's response to the new crown outbreak, a new poll released on the 23rd showed that 73 percent of Republicans think the response is going well, while only 38 percent of all respondents agreed. On the other hand, 62 percent of voters said the U.S. response to the new outbreak was "terrible," but only 27 percent of Republicans said so.
    poll results showed clear differences between Republican respondents and others over the U.S. government's response, the Associated Press reported.
    . As of 7:27 a.m. Beijing time on August 24, there were more than 5.69 million confirmed cases and more than 176,000 deaths in the U.S., according to real-time statistics from Johns Hopkins University.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.